Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
As of Mar. 2024, Yubo International Biotech has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Yubo International Biotech Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Yubo International Biotech's Sloan Ratio %
For the Medical Instruments & Supplies subindustry, Yubo International Biotech's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Yubo International Biotech's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Yubo International Biotech's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Yubo International Biotech's Sloan Ratio % falls into.
Yubo International Biotech Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Yubo International Biotech's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -0.367 (Jun. 2023 ) + 0.006 (Sep. 2023 ) + -0.517 (Dec. 2023 ) + -0.41 (Mar. 2024 ) = $-1.29 Mil.
Yubo International Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -0.153 (Jun. 2023 ) + 0.005 (Sep. 2023 ) + -0.558 (Dec. 2023 ) + -0.12 (Mar. 2024 ) = $-0.83 Mil.
Yubo International Biotech's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was 0 (Jun. 2023 ) + 0 (Sep. 2023 ) + 0 (Dec. 2023 ) + -0.03 (Mar. 2024 ) = $-0.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Yubo International Biotech (OTCPK:YBGJ) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Mar. 2024, Yubo International Biotech has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.
Yubo International Biotech Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of Yubo International Biotech's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
Yubo International Biotech (Yubo International Biotech) Business Description
Yubo International Biotech Ltd is a technology company focused on the research and development and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages, and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of nebulizers containing frozen tubes with medical fluid and from the sale of oral liquids health products. The nebulizers are sold directly to consumers on its online e-commerce platform.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
YBGJ has been successfully added to your 